BioPharma Resources

Therapeutic area

Neurology

Alzheimer's, Parkinson's, multiple sclerosis, epilepsy, migraine and ALS. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

19

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

127

Industry-sponsored

Recruiting Phase 3

103

Industry-sponsored

Recruiting Phase 4 (post-approval)

13

Industry-sponsored

Recent approvals

All
  • Klygefa (Gefurulimab) · Alexion Pharm NovelOrphanNov 13, 2026

    To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

  • Juvmo (Tavapadon) · Abbvie NovelSep 25, 2026

    To treat Parkinson's disease in adults

  • Isembyld (Apitegromab-Mstn) · Scholar Rock INC NovelPriority reviewOrphanSep 11, 2026

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Tauklarify (Florquinitau F-18) · Cerveau Lantheus NovelAug 13, 2026

    To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

  • Orzeyful (Oveporexton) · Takeda Pharms USA NovelPriority reviewOrphanAug 5, 2026

    To treat narcolepsy type 1

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMar 24, 2026

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Subvenite (Lamotrigine) · Owp Pharms Sep 16, 2025
  • Imaavy (Nipocalimab-Aahu) · Janssen Biotech NovelPriority reviewOrphanApr 29, 2025

    To treat generalized myasthenia gravis

  • Kisunla (Donanemab-Azbt) · Eli Lilly CO NovelBreakthrough therapyPriority reviewJul 2, 2024

    To treat Alzheimer's disease

  • Vigafyde (Vigabatrin) · Pyros Pharms OrphanJun 17, 2024
  • Duvyzat (Givinostat Hydrochloride) · Italfarmaco Spa NovelPriority reviewOrphanMar 21, 2024

    To treat Duchenne muscular dystrophy in individuals aged 6 years and older

  • Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca Ab NovelOrphanDec 21, 2023

    To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

  • Agamree (Vamorolone) · Catalyst Pharms NovelOrphanOct 26, 2023

    To treat Duchenne muscular dystrophy

  • Zilbrysq (Zilucoplan Sodium) · Ucb INC NovelOrphanOct 17, 2023

    To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

  • Rystiggo (Rozanolixizumab-Noli) · Ucb INC NovelPriority reviewOrphanJun 26, 2023

    To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • OrelabrutinibICP-022Phase 311 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies

  • AzetukalnerXEN1101Phase 39 trials

    Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder

  • EmpasiprubartARGX-117Phase 39 trials

    argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • ALKS 2680AlixorextonPhase 37 trials

    Alkermes, Inc. · Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

  • CorabotaseIPN10200Phase 37 trials

    Ipsen · Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines

  • IMVT-1402Phase 37 trials

    Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • BHV-7000Phase 36 trials

    Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder

  • CagriSemaCagrilintide B and Semaglutide IPhase 36 trials

    Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension

  • FenebrutinibRO7010939, GDC-0853Phase 36 trials

    Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive

Largest recruiting Phase 3 trials

All

More: Neurology news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.